First Time Loading...

Concert Pharmaceuticals Inc
NASDAQ:CNCE

Watchlist Manager
Concert Pharmaceuticals Inc Logo
Concert Pharmaceuticals Inc
NASDAQ:CNCE
Watchlist
Price: 8.37 USD Market Closed
Updated: Apr 27, 2024

Income Statement

Earnings Waterfall
Concert Pharmaceuticals Inc

Revenue
42k USD
Operating Expenses
-160.3m USD
Operating Income
-160.3m USD
Other Expenses
-3.7m USD
Net Income
-164m USD

Income Statement
Concert Pharmaceuticals Inc

Rotate your device to view
Income Statement
Currency: USD
Jun-2013 Sep-2013 Dec-2013 Mar-2014 Jun-2014 Sep-2014 Dec-2014 Mar-2015 Jun-2015 Sep-2015 Dec-2015 Mar-2016 Jun-2016 Sep-2016 Dec-2016 Mar-2017 Jun-2017 Sep-2017 Dec-2017 Mar-2018 Jun-2018 Sep-2018 Dec-2018 Mar-2019 Jun-2019 Sep-2019 Dec-2019 Mar-2020 Jun-2020 Sep-2020 Dec-2020 Mar-2021 Jun-2021 Sep-2021 Dec-2021 Mar-2022 Jun-2022 Sep-2022
Revenue
Revenue
24
N/A
24
+2%
25
+5%
21
-17%
5
-77%
9
+76%
9
-1%
8
-4%
60
+637%
58
-4%
67
+16%
66
-2%
12
-81%
11
-14%
0
-98%
0
-50%
0
N/A
144
N/A
144
N/A
154
+7%
154
N/A
11
-93%
11
N/A
1
-90%
1
N/A
1
N/A
1
N/A
0
N/A
6
N/A
8
+23%
8
N/A
8
N/A
34
+324%
33
-3%
33
+0%
33
N/A
1
-98%
0
-93%
Operating Income
Operating Expenses
(31)
(30)
(30)
(31)
(32)
(36)
(39)
(41)
(44)
(42)
(42)
(46)
(48)
(49)
(51)
(51)
(50)
(51)
(51)
(53)
(55)
(59)
(66)
(73)
(78)
(79)
(80)
(78)
(78)
(80)
(81)
(86)
(92)
(99)
(110)
(122)
(158)
(160)
Selling, General & Administrative
(8)
(8)
(8)
(9)
(9)
(10)
(12)
(12)
(13)
(13)
(13)
(14)
(14)
(14)
(14)
(16)
(18)
(19)
(21)
(21)
(21)
(23)
(23)
(23)
(22)
(21)
(20)
(19)
(19)
(19)
(19)
(19)
(20)
(21)
(22)
(22)
(27)
(27)
Research & Development
(23)
(22)
(22)
(22)
(23)
(26)
(28)
(29)
(31)
(30)
(29)
(32)
(34)
(35)
(37)
(35)
(32)
(31)
(30)
(31)
(32)
(36)
(43)
(50)
(56)
(58)
(60)
(58)
(58)
(61)
(62)
(66)
(71)
(77)
(88)
(100)
(131)
(133)
Depreciation & Amortization
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
(0)
(0)
(0)
(0)
(0)
(0)
(0)
(0)
(0)
(0)
(0)
(0)
(0)
(0)
Operating Income
(7)
N/A
(6)
+17%
(4)
+27%
(10)
-123%
(27)
-174%
(27)
-2%
(31)
-11%
(33)
-8%
17
N/A
15
-7%
25
+61%
20
-21%
(36)
N/A
(38)
-8%
(51)
-34%
(51)
+1%
(50)
+1%
93
N/A
93
-1%
101
+9%
100
-1%
(48)
N/A
(56)
-15%
(72)
-30%
(77)
-7%
(78)
-1%
(79)
-1%
(77)
+2%
(71)
+8%
(72)
-2%
(73)
-1%
(78)
-7%
(59)
+25%
(66)
-13%
(78)
-17%
(90)
-16%
(157)
-76%
(160)
-2%
Pre-Tax Income
Interest Income Expense
(2)
(2)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(0)
(0)
0
0
0
0
0
0
(0)
0
(0)
1
1
(0)
(1)
(1)
(0)
1
1
(0)
(1)
(2)
1
0
(0)
(3)
(6)
(4)
(4)
Non-Reccuring Items
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
(1)
(1)
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Total Other Income
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4
4
4
4
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Pre-Tax Income
(10)
N/A
(8)
+19%
(6)
+24%
(11)
-87%
(28)
-150%
(29)
-3%
(32)
-10%
(34)
-6%
16
N/A
15
-6%
25
+64%
20
-20%
(35)
N/A
(38)
-8%
(51)
-33%
(50)
+1%
(50)
+1%
92
N/A
95
+4%
104
+9%
104
N/A
(43)
N/A
(56)
-28%
(73)
-31%
(79)
-8%
(79)
+0%
(78)
+0%
(77)
+2%
(71)
+7%
(73)
-2%
(75)
-3%
(77)
-3%
(59)
+24%
(66)
-13%
(80)
-21%
(95)
-19%
(162)
-70%
(164)
-1%
Net Income
Tax Provision
0
0
0
0
0
0
0
0
(1)
(0)
(0)
0
0
0
0
0
0
(2)
0
0
0
2
(0)
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Income from Continuing Operations
(10)
(8)
(6)
(11)
(28)
(29)
(32)
(34)
15
15
24
19
(35)
(38)
(51)
(50)
(50)
90
96
105
104
(41)
(56)
(73)
(79)
(79)
(78)
(77)
(71)
(73)
(75)
(77)
(59)
(66)
(80)
(95)
(162)
(164)
Net Income (Common)
(10)
N/A
(8)
+19%
(6)
+24%
(11)
-87%
(28)
-150%
(29)
-3%
(32)
-10%
(34)
-6%
15
N/A
15
-5%
24
+66%
19
-20%
(35)
N/A
(38)
-8%
(51)
-33%
(50)
+1%
(50)
+1%
90
N/A
96
+7%
105
+9%
104
0%
(41)
N/A
(56)
-36%
(73)
-31%
(79)
-7%
(79)
+0%
(78)
+0%
(77)
+2%
(71)
+7%
(73)
-2%
(75)
-3%
(77)
-3%
(59)
+24%
(66)
-13%
(80)
-21%
(95)
-19%
(162)
-70%
(164)
-1%
EPS (Diluted)
-0.87
N/A
-0.71
+18%
-0.54
+24%
-1.22
-126%
-1.56
-28%
-1.59
-2%
-1.74
-9%
-1.8
-3%
0.67
N/A
0.66
-1%
1.03
+56%
0.86
-17%
-1.59
N/A
-1.71
-8%
-2.27
-33%
-2.24
+1%
-2.15
+4%
3.84
N/A
4.18
+9%
4.5
+8%
4.45
-1%
-1.76
N/A
-2.39
-36%
-3.12
-31%
-3.31
-6%
-3.3
+0%
-3.27
+1%
-2.64
+19%
-2.26
+14%
-2.31
-2%
-2.29
+1%
-2.27
+1%
-1.72
+24%
-1.95
-13%
-2.25
-15%
-2.59
-15%
-3.51
-36%
-3.3
+6%

See Also

Discover More